#392 - 基因检测：何时有价值、如何选择合适的检测以及如何处理结果

大家好。

Hey, everyone.

欢迎收听《Drive》播客。

Welcome to the Drive podcast.

我是你们的主持人阿提亚。

I'm your host, Attia.

这个播客、我的网站，还有每周的通讯，核心目标都是把长寿科学转化成每个人都能理解的内容。

This podcast, my website, and my weekly newsletter all focus on the goal of translating the science of longevity into something accessible for everyone.

我们的宗旨是提供最优质的健康与养生内容，为此我们组建了一支出色的分析团队来实现这个目标。

Our goal is to provide the best content in health and wellness, and we've established a great team of analysts to make this happen.

对我来说，最重要的是不依赖付费广告来提供这些内容。

It is extremely important to me to provide all of this content without relying on paid ads.

为此，我们的所有工作都完全依靠会员的支持才得以实现。

To do this, our work is made entirely possible by our members.

作为回报，我们为会员提供独家内容和额外福利，这些都是免费用户无法享受到的。

And in return, we offer exclusive member only content and benefits above and beyond what is available for free.

如果你想更深入地了解这个领域，我们的目标就是让会员获得远超订阅费用的价值。

If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription.

如果你想了解更多关于高级会员权益的信息，请访问 peterattiamd.com/subscribe。

If you want to learn more about the benefits of our premium membership, head over to peterattiamd.com slash subscribe.

欢迎收听今天这期《Drive》节目。

Welcome to today's episode of The Drive.

在医学领域，基因检测既让人着迷，也常常让人困惑。

Few areas in medicine generate as much fascination and as much confusion as genetic testing.

这里的直觉其实是有道理的。

The basic intuition here is sound.

既然DNA在人体生理机制中起着如此关键的作用，那么测序它原则上应该能帮助我们更清晰地理解健康与疾病。

If DNA contributes so strongly to our biological machinery, then sequencing it should, in principle, help us understand health and disease more clearly.

确实，有些基因检测结果可能彻底改变一个人的人生。

It's true that some genetic tests can be genuinely life changing.

但同样真实的是，另一些检测的参考价值还不如星座运势。

But it's equally true that others are barely more useful than a horoscope.

大多数情况都处于中间地带，远比外界的吹捧或怀疑所暗示的要复杂得多。

Most fall somewhere in between, in a gray zone that is far more nuanced than either the hype or the skepticism would suggest.

所以今天，我想帮大家建立一个清晰实用的框架，来理性看待基因检测。

So today I want to build a practical framework for thinking clearly about genetic testing.

我会讨论基因检测能做什么、不能做什么，为什么大多数基因检测结果都是概率性的，而不是确定性的，以及为什么直接测量表型往往比单靠DNA推算风险更有价值。

Through this I'll discuss what genetic tests can and can't do, why most genetic tests are probabilistic rather than deterministic, and why directly measuring the phenotype is often more useful than inferring risk from DNA alone.

我还会梳理一下，在主要疾病类别——也就是四大主要死因中，基因检测在哪些方面最有帮助，在哪些方面其实远没有人们想象的那么有效。

I'll also walk through where genetics can be most informative across the major disease categories, the four horsemen, and where it is much more limited than people assume.

最后，我会讲讲如何选择合适的检测类型，如何解读结果，以及如何避免一个非常普遍的误区：获取了更多信息，却没有获得更清晰的判断。

Finally, I'll talk about how to choose the right test or type of test, how to interpret the results, and how to avoid the very common mistake of getting more information without getting more clarity.

那么，不多说了，希望你们喜欢这一期的《The Drive》。

So, without further delay, I hope you enjoy this episode of The Drive.

最近，有位患者问我一个我经常被问到的问题。

Recently, a patient asked me a question that I hear all the time.

我该做基因检测吗？

Should I be doing genetic testing?

听起来是个简单的问题，但实际上它提供的信息非常有限，因为这句话可以有好多层意思。

It sounds like a simple question, but in reality it doesn't tell me very much because the question can mean a lot of different things.

比如，可能是你担心自己得阿尔茨海默病的风险，想知道该不该测APOE基因型。

You know, it could mean I'm worried about my risk of Alzheimer's disease, should we test for APOE genotype?

也可能是你母亲死于乳腺癌，你想弄清楚自己有没有携带BRCA基因突变。

It could mean my mother died of breast cancer, should I find out whether or not I carry a BRCA mutation?

还可能是想问，基因检测能不能帮我们选出最适合你降血脂的药物。

It could mean, will genetic testing help determine the best medication to address my lipids?

更常见的情况是，这个问题其实问得更宽泛：我最有可能得哪些病？

Or more commonly, it means something much broader: what diseases am I most likely to get?

而最后这种，才是大多数人真正关心的。

And that last question is really what most people have in mind.

我当然明白为什么会这样。

And I, of course, understand why.

人们总觉得，DNA就像是未来健康的蓝图，只要读得够仔细，就能提前知道会遇到什么健康问题，以及该怎么应对。

The notion that your DNA might serve as the kind of blueprint for your future health, that if you could read it closely enough, it would tell you what problems are coming and what to do about them.

这个想法确实非常吸引人。

That is an extraordinarily compelling idea.

如果我们真能有一个测试，准确告诉你最可能患上哪些疾病，以及该如何预防，那将是医学上的一次重大突破。

If we truly had a test that could reliably tell you which diseases you were most likely to develop and exactly how to prevent them, that would be a genuine game changer for medicine.

而这份承诺——或者至少是这份承诺的某种版本——正是许多公司试图推销的东西。

And that promise, or at least some version of that promise, is what many companies have tried to sell.

基因检测被宣传成能告诉你一切：该吃什么饮食、怎么锻炼、需要补充哪些营养品，甚至你的身体处理解毒或甲基化的能力如何。

Genetic testing has been marketed as a way to tell you everything from what diet you should eat, to how you should exercise, to which supplements you need, to how well your body handles things like detoxification or methylation.

但这时候我们必须停下来，更严谨地看待这个问题，因为现实远没有这么理想。

But this is where we have to slow down and be much more precise, because that's not quite the reality we live in.

基因检测确实有其用处。

Genetic testing can absolutely be useful.

在某些情况下，它甚至能带来深远的影响，改变人生。

In some cases, it can be very useful, even life altering.

在一些情形下，它能显著改变筛查策略、影响治疗决策、明确风险，或为家人提供关键信息。

There are situations where it can meaningfully change screening, influence treatment decisions, clarify risk, or provide critical information for family members.

但也有许多情况，基因检测带来的信息非常有限，甚至被过度宣传，真正有用的答案其实来自直接的临床评估，比如验血、影像检查、家族病史等。

But there are also many situations where it adds very little, where it's oversold, or where the better answers come not from genetics at all, but from directly measuring the phenotype through blood work, imaging, family history, or other clinical evaluation.

所以真正该问的，不是我该不该做基因检测。

So the real question is not simply should I do genetic testing?

真正该问的是：我想弄清楚什么？基因检测是不是解决这个问题的最佳方式？

The real questions are what exactly am I trying to learn and is genetic testing the best tool to answer that?

如果是，那到底该选哪种检测？

If so, what kind of test is actually appropriate?

如果得到了结果，它会真正改变我接下来的行动吗？

And if I get an answer, will it change anything meaningful about what I do next?

今天我想用这种方式来探讨这个问题。

That's how I'd like to approach this discussion today.

在讨论基因检测哪些地方有用、哪些地方没用之前，我觉得有必要先回过头来看看它的历史，因为很多人对基因检测的期待，其实还停留在过去的时代。

Before getting into where genetic testing is useful, and where it's not, I think it's worth stepping back for a moment and talking a bit about the history, because many of the assumptions people still carry about what genetic testing can deliver are leftovers from an earlier era.

我们现在所处的世界，测一个人的全基因组已经几乎成了家常便饭。

We now live in a world where sequencing a human genome feels almost routine.

现在做基因测序便宜多了，也更容易获取，技术上也简单了不少。

It's far less expensive than it used to be, increasingly accessible, and technically much easier to obtain.

但这种普遍性掩盖了这项能力其实才出现没多久的事实。

But that normalization obscures how recent this capability actually is.

人类基因组的第一份草图是2001年发布的，人类基因组计划在2003年基本宣告完成。

The first draft of the human genome was published in 2001, and the Human Genome Project was declared essentially complete in 2003.

也就是说，我们距离第一次拥有完整的人类DNA图谱，才过了二十多年。

So we are only a little more than two decades removed from the first time we had a comprehensive map of human DNA.

当时人们的期望非常高，这其实也很自然，完全可以理解。

At the time, expectations were extraordinarily high, and to be fair, understandably so.

如果你突然能读取一个人的完整基因密码，觉得医学上很多难题会变得容易理解，这想法并不离谱。

If you suddenly gained the ability to read the full genetic code of a human being, it was not unreasonable to think that many of medicine's biggest problems would become much easier to understand.

癌症、心血管疾病、神经退行性疾病、精神类疾病，这些病看起来一旦搞清了遗传基础，就会好对付得多。

Cancer, cardiovascular disease, neurodegeneration, psychiatric illnesses, these all seemed like conditions that might become far more tractable once their genetic basis was decoded.

但实际情况并没有完全如预期那样发展。

This is not exactly what happened.

但这并不意味着人类基因组计划失败了。

Now, that does not mean the Human Genome Project failed.

它是一项非凡的科学成就，确实创造了实际价值，尤其在罕见单基因疾病、部分肿瘤学领域以及药物基因组学方面。

It was an extraordinary scientific achievement, and it created real value, especially in rare monogenic diseases, in some aspects of oncology and in pharmacogenetics.

但它并没有实现当初人们对它所寄予的最广泛那些期望。

But it did not deliver on the broadest version of the promises attached to it.

人们原本以为，一旦掌握了序列，就能迅速理解其功能。

The assumption was that once we knew the sequence, we would quickly understand function.

以为只要读出这段代码，就能直接明白疾病是如何运作的，以及如何预防或治疗它。

That reading the code would tell us, more or less directly, how disease worked and how to prevent or treat it.

这种期望遇到挫折的部分原因，在于人类基因组的规模和复杂性实在太大。

Part of the reason that expectation ran into trouble is the sheer scale and complexity of the human genome.

它大约包含两万个基因，以及六十亿个碱基对。

It contains roughly 20,000 genes and about 6,000,000,000 total base pairs.

我们每个人在基因组的数百万个位置上都彼此不同，其中包括大约五百万个单核苷酸变异，还有大量其他插入、缺失和结构变化。

Each of us differs from one another at millions of places across the genome, including roughly 5,000,000 single nucleotide variants, plus many other insertions, deletions, and structural changes.

这些变异中，有些影响外貌特征，有些影响患病风险，还有很多看起来根本没什么作用。

Some of these variants affect physical traits, some affect our risk for disease, and many appear to do absolutely nothing.

但就连这样的描述也还是简化了问题，因为人们一听到基因，往往只想到直接编码蛋白质的那部分DNA。

And even this description understates the complexity because when people hear genes, they often think only about the part of DNA that codes directly for proteins.

而实际上，编码蛋白质的DNA区域只占基因组的1.5%。

But those protein coding regions of DNA make up only 1.5% of the genome.

绝大部分是非编码区，过去还被轻率地称为‘垃圾DNA’。

The vast majority is non coding, what used to be dismissed as so called junk DNA.

我们现在知道，其中很大一部分其实起着关键的调控作用，决定基因在何时、何地、以多强的力度表达蛋白质。

We now know that much of it plays a critical regulatory role, controlling when genes are turned on or off, where, and how strongly proteins are expressed.

所以，挑战不只是找出编码区的变异。

So the challenge isn't just identifying variations in the coding regions.

非编码区的变异也可能极其重要，哪怕我们目前还说不清它们具体意味着什么。

Variation in the non coding genome may matter enormously even when we don't yet fully understand what it means.

回头来看，花费27亿美元完成基因组测序，可能反而是相对简单的部分。

In hindsight, the $2,700,000,000 task of sequencing the genome may have actually been the easier part.

准确解读这段序列，以及我们该如何利用它，才是更大的挑战。

Accurately interpreting that sequence, and what we should do with it, is the far bigger challenge.

要理解这一点，最好先有个清晰的思维模型，明白基因变异到底是怎么引发疾病的。

To understand why, it helps to have a working mental model of how genetic variants actually produce disease.

DNA本质上是一套指令。

DNA is essentially a set of instructions.

这些指令会被转录成RNA，再翻译成蛋白质——它们是执行身体几乎所有生物功能的分子机器。

Those instructions get transcribed into RNA, which is then translated into proteins, the molecular machines that carry out virtually every biological function in the body.

这些指令的改变被称为基因变异，通俗点说就是突变，其实这两个词指的是同一件事。

A change in those instructions is called a gene variant or, more colloquially, a mutation, though these things mean the same thing.

很多时候这种改变没什么影响，但有时会导致蛋白质折叠错误、功能异常，或者根本无法产生。

Often the change is inconsequential, but sometimes it results in a protein that doesn't fold correctly, doesn't function as intended, or isn't produced at all.

正是这些功能失常的蛋白质，最终决定了表型——也就是身体可观察、可测量的输出，从化验数值到症状，再到疾病。

And it is that dysfunctional protein that ultimately shapes the phenotype, the observable, measurable output of the body from a lab value to a symptom to a disease.

这就是分子生物学的中心法则：信息只能单向流动，从DNA到RNA，从RNA到蛋白质，再从蛋白质到表型。

This is the central dogma of molecular biology, meaning information flows in one direction from DNA to RNA, RNA to protein, and protein to phenotype.

对于少数几种疾病，从基因到功能异常的蛋白质再到疾病，这条路径相对直接。

For a small number of diseases, there is a relatively direct line from gene to dysfunctional protein to disease.

但真正重要的那些疾病，情况要复杂得多。

But for the conditions that matter most, the story is much more complex.

即使是在遗传因素起重要作用的疾病中，通常也是由众多基因与环境因素之间的复杂相互作用引发的。

Even diseases where genetics matter a great deal tend to arise from countless interactions among many genes and environmental triggers.

在深入讨论具体疾病或检测之前，我们得先调整好对遗传检测的预期。

Before we dig into specific diseases or tests, it's important that we calibrate our expectations.

基因检测可能很有用，有时甚至非常有用，但它并不是健康的完美蓝图，也不能取代表型数据。

Genetic testing can be useful, sometimes very useful, but it is not a perfect blueprint for health and it does not replace phenotypic data.

换句话说，要想让基因检测真正有用，我们得有信心：知道某个基因变异确实能提供临床相关的指导。

Put another way, for genetic testing to be useful, we need to have some confidence that learning the genetic variant will actually inform something clinically.

所以，基于这一点，我们来谈谈需要关注的主要局限性。

So, with this in mind, let's discuss the major limitations we need to consider.

第一个局限性，也是最重要的一点，就是遗传学里我们讨论的大多数东西都是概率，而不是确定性。

The first limitation, and really the most important one, is that most things we talk about in genetics are probabilities, not guarantees.

问题的一部分在于，我们大多数人最初接触遗传学时，都是通过一个极度简化的模型。

Part of the problem is that most of us were introduced to genetics through a very simplified model.

在高中生物课上，遗传学是通过孟德尔遗传来教授的。

In high school biology class, genetics is taught through Mendelian inheritance.

我们学过显性性状、隐性性状，有时候也提到半显性性状。

We learned about dominant traits, recessive traits, sometimes called semi dominant traits.

我们画过庞尼特方格。

We drew Punnett squares.

我们把白花和红花杂交，结果得到了白花、红花或者粉花。

We crossed a white flower with a red flower and got a white, red or pink flower.

这种逻辑很清晰，结果是明确的，基因型和表现型之间的关系看起来也相当直接。

The logic is clean, the outcomes are discrete, and the relationship between genotype and phenotype appears relatively straightforward.

对于少数性状和疾病来说，这个框架确实有用。

And for a small number of traits and diseases, that framework is actually useful.

确实存在一些情况，单个基因突变会产生显著且相对可预测的影响，这就是我们说的高外显率突变。

There are cases where a single mutation has a large and fairly predictable effect, what we call high penetrance mutations.

正是这些情况，让遗传学一开始看起来如此有希望。

And those cases are part of what makes genetics seem so promising in the first place.

亨廷顿病可能是最极端的例子。

Huntington's disease is probably the most extreme example.

HTT基因通常包含一段重复的CAG序列。

The HTT gene normally contains a stretch of repeated CAG sequences.

这些只是碱基对的简写形式。

Those are just the base pairs and shorthand.

在亨廷顿病中，这个CAG重复序列会异常延长。

In Huntington's disease, this CAG repeat is abnormally expanded.

当这个延长的基因被翻译成蛋白质时，会产生一种对神经元有毒的突变型亨廷顿蛋白，尤其损害纹状体和大脑皮层。

When the expanded gene is translated into protein, it produces a mutant huntingtin protein that is toxic to neurons, particularly in the striatum and the cortex.

只要你携带的重复次数超过了致病阈值，就一定会患上亨廷顿病。

If you carry this expansion above the pathologic threshold, you will develop Huntington's disease.

毫无疑问。

Full stop.

在这个故事里，只要突变存在，疾病就一定会发生，几乎没有例外。

There is essentially no version of that story where the mutation is present and the disease doesn't follow.

但这种情况是特例，不是普遍规律。

But that's the exception, not the rule.

对于大多数人关心的那些疾病——心脏病、癌症、糖尿病、大多数精神疾病——遗传的作用根本不是这样的。

For the vast majority of conditions that people care aboutheart disease, cancer, diabetes, most psychiatric illnessesthat is simply not how genetics work.

这些病不是单一基因决定单一疾病的简单问题。

These are not one gene, one disease problems.

它们是由许多基因共同作用的结果，每个基因通常只带来一点点风险，再加上环境、行为、衰老和偶然因素的影响。

They are shaped by the combined effects of many genes, each often contributing only a small amount of risk, layered on top of environment, behavior, aging, and chance.

这意味着，即使你携带了增加患病风险的基因变异，也可能一辈子都不会发病。

Which means, you can carry a variant associated with increased risk and never develop the disease.

同样，即使你没有任何已知的高风险基因变异，也照样可能得病。

And you can lack any known high risk variant and still develop the disease anyway.

遗传只是改变了患病的概率分布。

The genetics shift the probability distribution.

它并不能决定最终结果。

It doesn't write the ending.

没有BRCA突变的人也会得乳腺癌，而携带两个ApoE4拷贝的人也可能一辈子都不会得阿尔茨海默病。

People without a BRCA mutation get breast cancer, and people with two copies of ApoE4 never develop Alzheimer's disease.

基因确实重要，但它们几乎总是和其他基因以及各种环境因素共同作用，而这些因素我们的检测很可能永远无法完全捕捉。

The genes matter, but they are almost always operating alongside other genes and other inputs that our tests will likely never fully capture.

第二个局限在于，我们获取基因数据的能力，已经远远超过了我们解读它的能力。

The second limitation is that our ability to generate genetic data has moved faster than our ability to interpret it.

这一点在检测范围扩大时尤为明显。

This is especially true as tests get broader.

你查看的基因组范围越广，就越有可能发现某些异常。

The more of the genome you look at, the more likely you are to find something.

但发现异常，并不等于发现有意义的异常。

But finding something is not the same as finding something useful.

即使实验室已经尽力筛选报告内容，更广泛的检测仍然会带来大量需要解读的信息。

And even when a lab does a good job limiting what it reports, broader testing still increases the amount of information that has to be interpreted.

现在测一个基因组只需要几百美元。

We can now sequence a genome for a few $100.

但变异太多了，相互作用太复杂，我们还有很多东西不明白。

But there are simply too many variants, too many interactions, and too many things we still do not understand.

所以基因检测的一个真正矛盾在于，检测范围越广，反而不一定更清晰。

So one of the real paradoxes of genetic testing is that broader testing doesn't always produce more clarity.

有时候，它只是带来了更多的不确定性。

Sometimes it just produces more ambiguity.

你得到了更多数据，但未必获得更多理解。

You get more data, but not necessarily more understanding.

第三个局限是，基因信息通常不如直接测量表型来得有用。

The third limitation is that genetic information is often less informative than directly measuring the phenotype.

如果你关心的东西能直接测量，那通常比用基因作为间接指标更靠谱。

If the thing you care about can be measured directly, that is usually a better place to start than a genetic proxy for it.

如果我想知道一个人心脏病发作的风险，我可以直接查他的胆固醇，再拍冠状动脉的影像。

If I want to know someone's risk for a heart attack, I can measure their cholesterol and image their coronary arteries.

我可以测他们的血压，问问他们是否吸烟。

I can take their blood pressure and ask whether or not they're smoking.

表型反映的是当下正在发生的事，综合了所有影响因素：基因、环境、行为、年龄，方方面面。

The phenotype tells me something that is happening right now, something integrated across all the contributing factors: genetic, environment, behavior, age, everything.

这是一种实时的反馈，可以直接采取行动。

It's a real time readout that can be acted upon.

基因检测是另一回事。

Genetic testing is something different.

它就像在读源代码，却不一定知道程序实际会怎么运行。

It's reading the source code without necessarily knowing how the program will run.

源代码当然重要，但程序的运行还受成千上万个其他因素影响，这些是序列本身无法体现的。

The source code matters, but the program is shaped by a thousand other inputs that the sequence alone doesn't capture.

最后，基因检测中最被忽视的一点，是这些信息可能带来的心理负担。

And finally, one of the most underappreciated aspects of genetic testing, the potential psychological weight of the information.

我遇过一些患者，得知自己没有遗传到父母身上的致病突变时，激动得几乎无法自持，当场在电话里哭了出来。

I have had patients who found out they did not inherit the same mutation carried by their parents suffered from a debilitating disease, and who were so overwhelmed with relief that they literally started to cry on a call.

基因检测的结果让他们终于弄清楚了一件多年来一直害怕的事。

The results of a genetic test gave them clarity around something they had been dreading for years.

这确实很有价值，哪怕在临床研究数据里看不到它的体现。

That's a real value, even if it doesn't show up in an outcome study.

但我也有患者拿到结果，显示自己患某种疾病的概率升高，从此陷入持续的焦虑。

But I've also had patients who received a result indicating an elevated risk for a disease and were consumed by anxiety about it.

这并没有让他们更积极地预防，反而长期被恐惧笼罩，严重影响了生活质量。

It didn't make them more proactive, it just made them more frightened in a way that affected their quality of life for years.

这一点很重要，因为信息并不因为真实就一定有用。

This matters because information is not automatically useful just because it's true.

如果一个检测结果只会引发恐惧或困惑，却无法带来筛查、治疗或规划上的积极改变，那它就会带来实实在在的代价。

A result that is likely to produce fear or confusion without changing screening, treatment or planning in a constructive way has real costs.

这些代价必须在决定做检测之前就纳入考量。

And those costs need to be a part of the calculation before you ever order a test.

明白了。

Okay.

那么，显而易见的问题是，既然基因检测有这么多局限性，我们该怎么判断它到底值不值得做呢？

So, the obvious question then is, if genetic testing has all of these limitations, how should we think about whether it's worth doing at all?

我觉得关键在于几个核心问题。

I think it boils down to a few important questions.

你到底想弄清楚什么？

What exactly are you trying to learn?

问题越具体，越有帮助。

The more specific the question, the better.

基因检测真的是解决这个问题的最佳方式吗？还是直接测量表型——也就是实际的生理表现——更简单、更有效？

Is genetic testing the best tool for this question, or is it easier and more informative to measure phenotype, the actual biological output, directly?

如果得到了结果，你会因此做出什么不同的决定？

If you get an answer, what will you do differently?

换句话说，这个检测会如何改变你的行为？

In other words, how will this test change your behavior?

第四，你心理上做好准备面对结果了吗？不管是好消息还是坏消息？

And four, are you mentally prepared for the answer, whether positive or negative?

基因检测应该能让人更有掌控感、更有信息量，如果结果只会让你恐慌，那可能就不适合你，至少目前不适合。

Genetics should be empowering and informative, so if the results are likely to just scare you, maybe it's not the right choice, at least for you.

这里没有绝对的对错，但我觉得大家在考虑做基因检测时，都应该问问自己这些问题。

There aren't necessarily right or wrong answers here, but these are the questions I think people should be thinking about when they consider genetic testing.

除此之外，还有一个因素能帮你判断基因检测可能有多大的用处。

Layered on top, I think there's one other consideration to help you determine how useful a genetic test is likely to be.

那就是你所关注的基因信号，它的影响到底有多大？

And that is how large is the effect of the genetic signal you're looking for?

是只让患病风险增加百分之五？

Is this something that nudges the disease risk by five percent?

还是能把风险提高十倍到二十倍？

Or is it something that changes the risk by 10 to 20 fold?

有了这个思路，我们现在可以来看看，在主要疾病类别中，基因检测到底在哪些方面真正有用，适用于哪些问题。

And so, with this framework in mind, we can now turn to the practical question across the major disease categories, where is genetic testing actually useful, and for what kinds of questions?

如果我们从最威胁寿命的疾病开始，第一个该关注的就是动脉粥样硬化性心血管疾病和代谢类疾病。

If we start with the biggest threats to lifespan, the first place to go is atherosclerotic cardiovascular disease and metabolic disease.

一般来说，对于这类疾病，常规进行基因检测的意义并不大。

And here, in general, I think the case for routine genetic testing is relatively weak.

这并不是说基因在这些疾病中不重要。

This is not because genetics don't matter in these conditions.

血脂、血压、胰岛素抵抗和肥胖都明显受到基因的影响。

Lipids, blood pressure, insulin resistance, and obesity are very clearly influenced by genetics.

但关键的临床问题是：知道基因型，是否比直接测量表型能带来更多的实用价值？

But the clinical question is not whether genes play a role, but whether knowing the genotype gives you something more useful than simply measuring the phenotype directly.

而大多数情况下，答案是否定的。

And most of the time, it does not.

以脂蛋白(a)为例。

Take Lp.

它的水平几乎完全由基因决定，主要受LPA基因影响。

Is almost entirely genetically determined, driven largely by the LPA gene.

事实上，它是导致心血管疾病最常见的遗传因素。

In fact, it is the most common hereditary driver of cardiovascular disease.

但知道某人携带影响LPA的变异，并不能告诉我真正需要的信息。

But knowing someone carries a variant that influences LPA doesn't actually tell me what I need to know.

我仍然会直接测量，因为测量结果比基因型提供更精确、更实用的数据。

I'm still going to measure it directly because the measurement gives me more precise, actionable information than the genotype does.

这个道理在所有情况下都适用。

The same logic applies across the board.

如果我想知道一个人有没有高血压，我就直接量血压。

If I want to know whether someone has hypertension, I measure their blood pressure.

如果我想评估胰岛素抵抗，我有直接的方法可以做。

If I want to assess insulin resistance, I have direct tools to do that.

当然，如果我想了解他们的LDL胆固醇或载脂蛋白B水平——这两项都受遗传影响很大——我直接测出来就行，还能观察他们对治疗的反应。

And of course, if I want to know their LDL cholesterol or ApoB concentration, both things that are highly influenced by genetics, I can simply measure those things and measure their response to therapy.

对于心血管和代谢疾病的主要诱因，我们早就掌握了最关键的信息。

For most of the major drivers of cardiovascular and metabolic disease, we already have access to the things that matter most.

而这些指标比遗传风险预测要实用得多。

And those things are far more actionable than a genetic estimate of predisposition.

但这并不意味着完全没有例外情况。

Now, that does not mean there are no exceptions.

家族性高胆固醇血症就是一个明显的例子。

Familial hypercholesterolemia is an obvious one.

如果一个人LDL明显偏高，且家族史提示单基因脂质紊乱，基因检测确实能提供有价值的确认。

If someone presents with a markedly elevated LDL and a family history suggesting a monogenic lipid disorder, genetic confirmation can be genuinely useful.

不一定是因为它会改变初始治疗方案，而是因为它能巩固诊断，并可能促使那些尚未察觉的亲属进行连锁筛查。

Not necessarily because it changes the initial treatment, but because it can solidify the diagnosis and potentially trigger cascading screenings in relatives who may be affected without knowing it.

还有一些更罕见的情况，某些基因变异会彻底改变我们对表型的解读。

There's also the rarer situations where specific variants change how we interpret the phenotype altogether.

比如SCARB1基因突变，会让HDL胆固醇看起来偏高，给人一种虚假的安全感，但实际上患者的心血管风险远比血脂报告所显示的要高得多。

SCARB1 mutations, for example, can cause HDL cholesterol to appear elevated in a way that looks falsely reassuring, when in reality, the patient's cardiovascular risk is substantially higher than their lipid panel implies.

我有个朋友就是被我发现了这个问题，他多年来一直以为自己的HDL高达100、LDL只有80，就完全不用担心了，结果钙化评分一查，发现血管里已经布满斑块。

I actually had a friend that I was able to catch this diagnosis in who had spent years believing that his HDL cholesterol of 100 milligrams per deciliter and his LDL cholesterol of 80 milligrams per deciliter meant he was free and clear of risk, when in reality, a calcium score revealed that he was riddled with disease.

这些突变虽然罕见，但它们说明了基因信息有时能揭示血脂报告看不到的关键问题，从而推动进一步的检查。

These mutations are rare, but they do illustrate where the genotype is actually telling you something that is not immediately obvious from a lipid panel and prompt additional testing.

还有一种情况我觉得值得提一下：基因信息改变了患者的行为，但并没有真正改变临床治疗方案。

And then there is another category that I think is worth acknowledging: cases where genetic information shifts behavior rather than truly changing clinical care.

我见过一些患者，之前一直抗拒服用降脂药，但看了基因检测结果后，他们终于同意开始治疗。

I've seen patients agree to start lipid lowering medication that they'd been resistant to after seeing genetic data that confirmed their risk.

我也见过一些长期受肥胖困扰的患者，得知自己携带多个与体重增加相关的基因风险变异后，感到释然，甚至觉得找到了解释。

I've seen patients who struggled with obesity for years find it meaningful, even relieving, to learn that they carry multiple genetic risk variants for weight gain.

并不是因为这改变了治疗方案，而是因为这让他们重新看待问题，不再觉得是自己意志力不足。

Not because it changed the treatment plan, but because it reframed the problem in a way that felt less like a personal failure.

这种心理上的转变是真实存在的，我不会轻视它。

That psychological shift is real and I don't dismiss it.

但它和‘检测揭示了表型无法体现的信息’是两回事。

But it is different from saying the test revealed something the phenotype could not.

在大多数情况下，临床线索其实早就存在了。

In most of these cases, the clinical information was already there.

基因检测只是改变了患者对这些信息的理解方式。

The genetics just changed how the patient related to it.

所以对于这一类情况，结论其实很明确。

So the conclusion for this category is fairly straightforward.

基因确实很重要，但对大多数人来说，它并不是首选的工具。

Genetics matter a lot, but for most people, it is not the right first tool.

先看临床表现。

Measure the phenotype.

如果临床表现中出现了某些具体线索——比如家族史说不通、实验室指标异常极端，或者症状提示单基因疾病——那时再考虑基因检测是否能提供额外信息。

If something in the clinical picture raises a specific question, a family history that doesn't add up, an unusually extreme lab value, a presentation that suggests a monogenic disorder, then consider whether genetic testing adds something.

但作为常规的起点，临床表现几乎总是比基因型更可靠。

But as a routine starting point, the phenotype almost always beats the genotype here.

不过，一旦我们从动脉粥样硬化性心血管疾病转向遗传性心脏疾病，问题就略有不同了。

Now, once you move outside of ASCVD into inherited cardiac conditions, the question changes a bit.

这时候，基因检测的说服力会更强。

This is where genetic testing can become more compelling.

因为确实存在一些遗传性综合征，涉及心律失常、心肌病和结构性心脏病，这些情况下的基因型可能揭示出常规检查或传统心血管风险指标无法发现的风险。

Because there are real inherited syndromes involving arrhythmia, cardiomyopathy, and structural heart disease where genotype may reveal risk that is not obvious from routine labs or standard cardiovascular risk markers.

当然，这些疾病我们也能检测，但实际并不常做。

Of course, these are also conditions we can test for, but may not do so nearly as regularly.

对于没有明显风险因素或症状的人，我们可能不会做心电图。

For individuals with no obvious risk factors or symptoms, we may not perform an EKG.

或者，我们可能只做一次，如果结果正常，就再也不做了。

Or, we may run these tests once and then never run them again if everything appears normal.

不过，像房颤这样的疾病，可能到中老年才会出现。

Conditions like atrial fibrillation, however, can arise later in life.

所以，年轻时心电图正常，并不意味着将来就不会出问题。

So, a normal EKG earlier in life doesn't necessarily preclude a future problem.

了解遗传风险，可能会促使我们更频繁地检查，从而更早发现潜在的致命问题。

Knowing about genetic risk may also prompt more regular testing that can catch a potential life threatening condition earlier on.

所以，这里的选择要么是给每个人做这些稍复杂的检查，要么就是找出谁更需要定期筛查。

So the options here are to run these somewhat more complex tests on everyone or find a way to determine who should get regular testing.

家族病史会很有帮助。

Family history can be helpful.

有家族成员突发心脏猝死或已知心脏问题的患者，通常适合接受常规筛查。

Patients with a family history of sudden cardiac death or known cardiac issues are probably good candidates for routine screening.

但仅靠家族史可能无法全面反映真实情况。

But family history alone may not give us the whole picture.

有些基因突变的外显率不完全，也就是说，并非所有携带者都会发病。

Some mutations are incompletely penetrant, meaning some but not all of the carriers are affected.

因此，完全有可能携带遗传风险因素，却没有任何家族病史。

So, it's entirely possible to have a genetic risk factor without a family history.

此外，家族中模糊的心脏病史可能指向多种不同疾病，而且并非所有患者都能提供完整详尽的病史，以支持更深入的检查。

Further, a vague family history of heart disease could mean any number of different conditions and not all patients are able to provide a complete, detailed history that would inform more advanced tests.

所以在这一领域，基因检测有时能揭示更具体的遗传风险，从而影响我们选择哪些检查以及何时进行。

So, in this domain, genetic testing can sometimes uncover a more specific inherited risk that may change what tests you order and when.

这并不意味着每个人都该去筛查所有可能的心律失常或心肌病基因。

This does not mean everybody should go out looking for every conceivable arrhythmia or cardiomyopathy gene.

但与动脉粥样硬化性心血管疾病相比，这类情况显然更能从遗传检测中获得额外价值。

But compared with ASCVD, this is clearly a category where genetics can provide more incremental value.

所以我觉得这属于中间地带，不适合对所有人进行广泛常规筛查，但当个人或家族史指向这方面时，进行检测就更有依据了。

So I would kind of put this in the middle category, not an area for broad routine testing in everyone, but clearly more defensible when the personal or family history points in that direction.

谈到癌症，情况就复杂多了，毕竟癌症本质上是一种遗传性疾病。

Cancer is where the conversation becomes much more nuanced, because cancer is, after all, a genetic disease.

但大多数癌症并不是由遗传性DNA引起的。

But most cancer is not due to inherited DNA.

绝大多数癌症源于体细胞突变，而不是生殖细胞突变。

The vast majority of cancers arise from what are called somatic mutations, as opposed to germline mutations.

这些是后天获得的突变，不是遗传来的，因此在常规基因检测中不会显示出来。

These are acquired mutations, not the inherited ones, And they won't appear on standard genetic tests.

事实上，根据大多数估计，只有大约百分之五的癌症是由遗传性生殖细胞突变引起的。

In fact, by most estimates, only about five percent of cancers are attributable to inherited germline mutations.

换句话说，大多数癌症患者在他们的遗传基因中并不会发现异常。

Put another way, most people who have cancer would not find anything unusual in their inherited genetics.

因此，没有发现致癌遗传突变，并不意味着将来就不会得癌症。

So the absence of cancer predisposing mutations certainly does not rule out the possibility of developing cancer later in life.

但百分之五也很重要，因为这类癌症通常由高外显率的基因突变引起，会大幅提高终身患病风险，而且一旦知晓这些突变，就能显著改变诊疗方案。

But five percent matters because the cancers that fall into this category tend to involve highly penetrant mutations that carry substantial elevated lifetime risk, and because knowing about them changes management in meaningful ways.

最典型的例子，我之前提过，就是BRCA1和BRCA2基因。

The clearest examples, which I've already mentioned, are BRCA1 and BRCA2.

携带BRCA突变的女性，患乳腺癌和卵巢癌的终身风险会急剧升高，高到足以支持加强筛查、药物预防，甚至预防性手术。

Women who carry BRCA mutations face drastically elevated lifetime risks of breast and ovarian cancer, high enough that enhanced screening, chemo prevention, and even prophylactic surgery can be appropriate.

但这些并不是唯一与乳腺癌和卵巢癌相关的基因。

But these are not the only breast and ovarian cancer genes.

它们还和胰腺癌、前列腺癌等其他癌症风险上升有关，这不仅扩大了临床意义，也让家族病史中的线索更加关键。

They are also associated with an increased risk of cancers such as pancreatic and prostate cancer, which broadens both the clinical implications and the family history clues that matter.

同样，林奇综合征由错配修复基因突变引起，会显著增加结直肠癌和其他几种癌症的风险。

Similarly, Lynch syndrome, caused by mutations in mismatch repair genes, dramatically increase the risk for colorectal cancer and several other cancers.

知道自己是否携带这些突变，能帮助调整筛查的频率和强度，从而挽救生命。

And knowing your status changes screening intensity and frequency in ways that saves lives.

这类情况对家人也有重要影响。

These types of conditions also have implications for family members.

一个携带BRIP1基因突变、增加卵巢癌风险的父亲，不会担心自己没有的器官会得癌。

A father who carries a mutation in BRIP1 that predisposes to ovarian cancer is not going to be concerned about his risk for cancer in an organ that he does not have.

但知道他携带这个突变，足以成为他女儿们去做基因检测的重要理由。

But knowing that he carries this variant is a very good reason for his daughters to get tested.

同样重要的是，家族中没有明显病史，并不等于就能排除携带这类基因突变的可能性。

Just as importantly, an apparent lack of family history does not entirely rule out the risk for having one of these mutations.

虽然不常见，但确实有一些患者携带高风险的致癌突变，而家族里却看不出任何异常。

While not the norm, there are certainly cases of patients carrying potent cancer predisposing mutations with an unremarkable family history.

那么，这是否意味着每个人都该做癌症基因检测呢？

So, does this mean everyone needs genetic testing for cancer?

不一定。

Not necessarily.

对于没有明显家族或个人癌症史的人来说，检出高外显率癌症突变的概率很低，因此不建议在人群中普遍开展常规检测。

For someone with no meaningful family or personal history of cancer, the pretest probability of finding a high penetrance cancer mutation is low enough that it's hard to justify routine testing on a population basis.

不过，我认为癌症筛查是个特例——即使没有明显家族史，个人也可以选择做检测，因为和心血管疾病不同，我们没有可靠的生物标志物可查，而这些突变的影响往往非常显著。

That said, I do think cancer is one area where an individual may opt for testing without notable family history because unlike cardiovascular disease, there is no biomarker we can assess, and the relative impact of these mutations tends to be quite high.

不过我要说明一下，大多数人结果都会是阴性。

Now, to be clear, most people will have a negative result here.

虽然阴性结果能让人安心，但我们也别忘了，百分之九十五的癌症还是由体细胞突变引起的。

And while that negative result can be reassuring, it's important that we don't lose sight of the fact that ninety five percent of cancers that arise are still somatic mutations.

这里我想强调一个关键的技术点，因为这是我在临床中最常遇到的虚假安全感来源。

There is one important technical point I want to make here because it's one of the most common sources of false reassurance I encounter.

消费级基因检测通常只筛查少数几种与癌症相关的突变。

Consumer genetic tests oftentimes only test a few different cancer predisposing mutations.

比如最初的23andMe检测，只覆盖了BRCA1和BRCA2基因中的三种致病突变。

The original 23andMe test, for example, assessed only three pathogenic mutations in BRCA1 and BRCA2.

但这两个基因里已知的致病变异有成千上万种。

But there are thousands of known pathogenic variants in these genes.

所以，如果患者告诉我他们的23andMe检测BRCA是阴性，这并不能说明他们没有重要的癌症突变。

So, if a patient tells me that their 23andMe results came back negative for BRCA, that does not really tell me that they don't have an important cancer mutation.

它只说明他们没有携带那三种研究得比较透彻的突变而已。

It just tells me that they don't have one of the three more well studied ones.

要进行有意义的癌症遗传风险评估，必须使用临床级别的基因面板检测，而不是消费级的基因检测产品。

For meaningful cancer genetic risk assessment, you need clinical grade panel testing, not a consumer genotype product.

癌症是种系基因检测最有用的领域之一，但前提是必须针对正确的问题，并清楚了解这项检测到底覆盖了哪些内容、没覆盖哪些内容。

So, cancer is one of the clearest areas where germline genetic testing can be very useful, but only when it is used to answer the right question, with a very clear understanding of what the test is and is not covering.

神经退行性疾病则是完全不同的另一类情况。

Neurodegenerative disease is a very different category.

因为在这里，了解风险和采取行动之间的平衡要脆弱得多，而且显而易见，这类疾病往往让患者在情感上最难应对。

Because here the balance between understanding risk and actionability is much shakier, and for obvious reasons, these diseases tend to be the most emotionally complex for patients to deal with.

最广为人知的例子当然是ApoE，这些年我们在播客里多次提到过。

The most familiar example is of course ApoE, something we've talked about a lot on this podcast over the years.

ApoE4是阿尔茨海默病最强的常见遗传风险因素，它能显著改变患病风险。

ApoE4 is the strongest common genetic risk factor for Alzheimer's disease, And it can shift risk in a meaningful way.

携带两个ApoE4拷贝的人，患阿尔茨海默病的风险可能是没有该突变者的15倍。

Individuals with two copies of APOE4 may have a risk of Alzheimer's disease up to 15 times higher than someone who does not have the mutation.

但这并不意味着命运已定。

But it is still not destiny.

并不是所有携带两个ApoE4基因拷贝的人都会患上阿尔茨海默病，而大约一半的阿尔茨海默病患者根本连一个APOE基因都没有，更别提两个拷贝了。

Not everyone who is homozygous for ApoE4, meaning has two copies, develops Alzheimer's disease, and roughly fifty percent of people with Alzheimer's disease do not carry even a single APOE gene at all, let alone two copies.

不过，我认为了解自己的APOE状态还是有其价值的，原因有几个。

That said, I think that knowing APOE status can be useful for a few reasons.

目前有一些新的治疗策略，比如我们之前在节目中讨论过的opacetropib，正在研究中，这些疗法对携带ApoE4的人群显示出特别的潜力，其理论基础是ApoE4会影响大脑和全身的脂质代谢。

There are emerging therapeutic strategies, such as opacetropib, which we've also covered on this podcast, being studied that specifically show promise in ApoE4 carriers, based on the hypothesis that ApoE4 affects lipid metabolism in both the brain and periphery.

虽然数据还处于早期阶段，但这确实是一个很好的例子，说明遗传信息未来有可能帮助医生为阿尔茨海默病这类严重疾病制定更个性化的治疗方案。

The data are still early, but it's a plausible example of where genetic information could begin to inform therapeutic decisions in a more personalized way, even for diseases as ravaging as Alzheimer's.

如果我们知道患者本身风险基线就比较高，也可能促使我们更积极地管理其他可改变的风险因素，比如血脂和代谢健康。

It may also make us more aggressive about managing other modifiable Alzheimer's disease risk factors, such as lipids and metabolic health, if we know the patient is starting from a higher baseline risk.

对某些患者，尤其是有痴呆家族史的人而言，了解自己的ApoE状态，更多是为了做人生规划，而不是为了治病。

For some patients, particularly those with a family history of dementia, knowing their ApoE status is less about medicine and more about planning.

在危机发生前很多年就讨论财务安排和长期照护意愿，远比在危机来临时才谈要容易得多。

It is far easier to discuss finances and long term care preferences many years before a crisis than during one.

除了ApoE之外，还有一些罕见但致病性很强的基因突变，会导致早发性或家族性严重神经退行性疾病，包括阿尔茨海默病、帕金森病、亨廷顿病，还有我之前提到的肌萎缩侧索硬化症。

Beyond ApoE, there are rare but highly penetrant mutations that drive early onset or familial forms of severe neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, Huntington's disease, as I mentioned earlier, and ALS.

像帕金森病和渐冻症这类疾病，并没有一个明确常见的遗传风险因素。

Diseases such as Parkinson's disease and ALS do not have one clear common genetic risk factor.

实际上，只有大约百分之十的病例是由已知的基因突变引起的。

Instead, only about ten percent of cases are due to known genetic mutations.

因此，如果父母或兄弟姐妹患病，尤其是发病年龄特别年轻，做基因检测可能是一个合适的选择。

And so for someone with a parent or sibling affected, especially at an unusually young age, genetic testing may be an appropriate option.

但在这一类疾病中，大规模人群筛查通常没有意义。

But broad population screening rarely makes sense in this category.

这些突变的发病率很低，而且与遗传性癌症突变不同，目前检测结果还无法对应明确的干预措施。

The prevalence of these mutations are low, and unlike hereditary cancer mutations, the results don't yet really map onto established interventions.

所以这里的检测几乎总是由具体的家庭情况驱动的个人决定。

So testing here is almost always a personal decision driven by a specific family circumstance.

与其他任何疾病相比，这里的检测价值更取决于你问的是什么问题。

More than any other type of disease, the value of testing here depends on the question being asked.

你是出于好奇，想了解自己患阿尔茨海默病的风险吗？

Are you trying to estimate Alzheimer's disease risk for curiosity's sake?

你是想确认自己是否携带了这种毁灭性家族综合征的基因突变吗？

Are you trying to determine whether or not you carry the mutation for a devastating familial syndrome?

你是想用这个结果来决定治疗方案或预防措施吗？

Are you trying to make treatment decisions or prevention decisions?

还是你真正关心的是未来规划——比如获取一些信息，帮助你安排长期的财务、职业甚至照护计划？

Or are you really asking a planning question, gaining information that may help inform long term financial, career, or even care decisions?

这些问题都值得探讨，但在做检测之前，必须认真权衡。

All of these are valid questions, but ones that should be very carefully considered before testing.

在这种情况中，检测带来的心理影响最为关键。

This is also the category where the psychological dimension of testing matters most.

这里的问题不只是信息是否准确，而是它对这个人本身是否真的有用。

Here the question is not just whether the information is true, but whether it is likely to be useful for that particular person.

没有放之四海而皆准的答案。

There are no universal right answers.

这完全因人而异，必须在检测前进行坦诚的沟通。

It is deeply patient specific, and it requires an honest conversation before the test is ever ordered.

一旦你把范围扩大到四大主要疾病之外，比如心理健康和复杂的慢性病，之前在心血管疾病中看到的那些问题又出现了。

Once you move into diseases outside of the four horsemen, areas like mental health and complex chronic conditions, the same themes we saw in ASCVD return.

基因确实有影响，但这并不意味着目前的基因检测能显著改变治疗方式。

Genetics clearly matter, but that does not mean that the current genetic testing changes care in a meaningful way.

基因对情绪障碍、压力反应和物质使用确实有作用。

The genetic influences on mood disorders, stress reactivity, and substance use are real.

但到目前为止发现的变异只解释了部分风险，还远不能比标准临床治疗更好地指导治疗。

But the variants identified so far explain only a modest fraction of overall risk, and they do not yet guide treatment in a way that outperforms standard clinical care.

当然，未来可能会有变化，但我们现在还没到那一步。

Of course, that may change in the future, but we are just not there yet.

这就让这个领域特别容易被夸大其词的宣传误导，尤其是那些功能医学检测套餐——它们检测一些常见变异，然后编出一套关于解毒、甲基化、炎症或神经递质平衡的故事。

And that makes this space particularly vulnerable to the hype that outruns the science, especially the functional medicine style panels that test common variants and then build a story around detoxification, methylation, inflammation, or neurotransmitter balance.

从‘这个变异在某个通路中起一定作用’，直接跳到‘你必须用这套补充方案’，中间的跳跃往往远远超出了现有证据的支持。

The leap from this variant plays some role in this pathway to therefore this is the supplement protocol you need is almost always much larger than the evidence justifies.

MTHFR 基因就是一个典型的例子。

MTHFR is a prime example of this.

这个基因的变异确实存在，也会在一定程度上影响叶酸代谢。

Variants in this gene are real, and they do alter folate metabolism to some degree.

但人们常常忽略的一点是，这些变异其实非常普遍。

But the thing that often gets left out is just how common these variants are.

多达百分之四十的人口携带其中一种或两种变异。

Up to forty percent of the population carries one or two copies of some of these variants.

你不妨仔细想想这意味着什么。

Think about what that means for a moment.

如果MTHFR变异真是导致疾病的主要原因，那在人群数据中应该能明显看出来。

If MTHFR variants were driving meaningful disease, we would expect to see it clearly in population level data.

但事实上，我们根本看不到。

But of course, we don't.

这些变异如此普遍，本身就说明它们的平均影响很小，因为自然选择会淘汰那些造成严重危害的变异。

The fact that these variants are so prevalent is itself strong evidence that their average effect is small, because natural selection tends to weed out variants that cause serious harm.

可偏偏在功能医学领域，MTHFR成了被过度检测、过度解读的典型例子。

And yet MTHFR has become one of the most over ordered and over interpreted findings in functional medicine.

患者经常被告诉，他们的疲劳、脑雾、焦虑或其他一大堆非特异性症状，都是由MTHFR基因变异引起的。

Patients are routinely told that their fatigue or brain fog or anxiety or a dozen other nonspecific symptoms are caused by MTHFR.

于是他们被要求执行激进的甲基化方案，而这些方案针对的变异，对绝大多数人来说其实根本没有临床意义。

And they are placed on aggressive methylation protocols based on a variant that for the vast majority of people, is clinically irrelevant.

仅仅检测出MTHFR变异，并不等于确诊，也不能解释那些神秘的症状，更不值得花大价钱去买那些所谓的‘专属’补充剂组合。

The mere presence of an MTHFR variant is not a diagnosis or an explanation for mysterious symptoms or reason to spend a fortune on specialized just for you supplement stacks.

一个基因突变可能在生物学上很有意思，但在临床上却没什么实际用途。

A mutation can be biologically interesting without being clinically actionable.

MTHFR可能是临床遗传学中最清楚体现这一区别的例子。

MTHFR is perhaps the clearest illustration of that distinction in all of clinical genetics.

但它绝不是唯一的一个。

But it is far from the only one.

事实上，只要你懂得怎么看，就能发现一种模式。

In fact, once you know what to look for, a pattern emerges.

找一个常见的变异，哪怕有点科学依据，就把它的重要性夸大，然后用它来证明某种补充剂方案的合理性。

Find a common variant with at least some science, inflate its importance, and then use it to justify a supplement protocol.

这些基因变异常常被解释得像性格测试或者星座运势一样。

Oftentimes, these variants are explained in a way that is akin to personality tests or astrological signs.

描述得刚好够模糊，让几乎每个人看了都觉得‘这说的不就是我吗’，却没意识到这些说法其实适用于所有人。

The description is just broad enough that practically everyone can read it and say, Wow, that describes me perfectly, without realizing that the information applies to everyone.

COMT以及其他与神经递质相关的基因，也是这套套路的常客。

COMT and other neurotransmitter related genes are another favorite for this playbook.

人们常根据一个常见的COMT变异，告诉你他们是多巴胺的‘快代谢型’或‘慢代谢型’。

A common COMT variant is often used to tell people that they are a fast or slow metabolizer of dopamine.

说这能解释你的性格、你的压力反应，还有——又是你该吃哪些补充剂。

That it explains their personality, their stress response, and yet again, which supplements they should take.

这里面确实有真实的生物学基础。

There is real biology here.

很多这类基因变异确实会影响多巴胺的代谢。

Many of these gene variants do affect dopamine metabolism.

但从一个常见且受环境影响的变异，直接跳到专属的性格画像或补充剂方案，就太过武断了。

But the jump from a common context dependent variant to a bespoke personality profile or supplement protocol is wildly overconfident.

还有所谓的排毒检测，通过分析细胞色素P450酶及其相关通路的常见变异，声称能反映你肝脏处理毒素的能力。

Then there are the so called detox panels, tests that assess common variants in cytochrome P450 enzymes and related pathways and present them as a window into your liver's ability to handle toxins.

这听起来挺科学，结果还常配上彩色图表，暗示你的排毒通路出了问题，需要——你猜怎么着——额外补充营养品。

The premise sounds scientific, and the results often come back with color coded charts implying that your detox pathways are somehow compromised and in need of, wait for it, supplemental support.

但这些报告通常不会告诉你，肝脏的解毒系统本身具有极强的冗余性。

What these reports usually leave out is that the liver's detoxification machinery is extraordinarily redundant.

一旦某条通路活性降低，其他通路往往会自动补上。

When one pathway is less active, others often compensate.

目前并没有任何临床证据表明，健康人仅因这些基因的常见变异就会出现所谓的‘排毒能力差’综合征。

There is no recognized clinical syndrome of poor detox in otherwise healthy people based on common variants in these genes.

人体早就靠自己解决了这个问题，根本不需要什么个性化的营养补充方案。

The body has been solving this problem for a very long time without personalized supplement stacks.

那些打着DNA检测旗号、号称能为你量身定制最佳饮食的基因检测，用的也是同一套话术。

Neutrogenomic tests that are marketed as a way to identify your perfect diet based on your DNA function similarly.

确实有一些研究发现，像FTO这样的基因突变，可能让人对某些特定饮食反应更好。

There are some studies linking mutations in genes like FTO to better outcomes from certain diets.